Clinical trials: Bronchogenic Carcinoma
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Pancreatic Cancer, Lung Cancer, Nonsmall Cell
Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)
Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned…
- Trial name
- BetterEveryDay (NCT04611867)
- Testing
- Supportive application with integrated weekly PRO
- Where
- Denmark
- Volunteers
- 274 people
- Sponsor
- Inna Chen, MD
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- SANOVO (NCT05009836)
- Testing
- Savolitinib, Osimertinib
- Where
- China
- Volunteers
- 412 people
- Sponsor
- Hutchmed
Non-Small-Cell Lung Cancer
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
This study aims to investigate the efficacy and safety of immuno-chemotherapy in combination of cryoablation as the first-line treatment of advanced NSCLC
- Trial name
- NCT06483009
- Testing
- Cryoablation
- Volunteers
- 20 people
- Sponsor
- Shanghai Chest Hospital
Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
The purpose of the study is to evaluate the usefulness and accuracy of the "LIFE-Lung Bronchoscopy" to identify early changes in lung tissues that show precancerous, cancer in situ (just beginning and not spread) and microscopic…
- Conditions
- Non-Small-Cell Lung Carcinoma, Head and Neck Squamous Cell Cancer, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00260598
- Testing
- LIFE Bronchoscopy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Pittsburgh
SCLC, Carcinoma, Small Cell
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
- Trial name
- NCT00046787
- Testing
- OSI-211 (Liposomal Lurtotecan)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Astellas Pharma Inc
Non-small Cell Lung Cancer
Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects
A phase I study to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetic, safety/tolerability and efficacy profiles of antroquinonol (Hocena®) in non-small cell lung cancer (NSCLC) subjects refractory to…
- Trial name
- Hocena (NCT01134016)
- Testing
- Antroquinonol
- Where
- 2 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- Golden Biotechnology Corporation
Neoplasms
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.
- Trial name
- NCT02817633
- Testing
- TSR-022, Nivolumab, TSR-042
- Where
- 89 sites in United States, South Korea and 1 more
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
Stage II-III Non-small Cell Lung Cancer
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable…
- Trial name
- neoR-TORCH (NCT06437977)
- Testing
- SBRT, Toripalimab
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported.
- Trial name
- NCT04777175
- Testing
- immunity therapy
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Yongchang Zhang
Carcinoma, Non-Small-Cell Lung
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
- Trial name
- REVEAL (NCT03761901)
- Testing
- 1L treatment, 2L Treatment, 3L treatment
- Where
- 15 sites in Belgium
- Volunteers
- 141 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)
The purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage III NSCLC.
- Trial name
- NCT00132665
- Testing
- A: Radiotherapy alone, B: CBDCA and Radiotherapy
- Where
- 37 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Japan Clinical Oncology Group
Pulmonary Function Assessment, Disease Free Survival
Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.
- Conditions
- Pulmonary Function Assessment, Disease Free Survival, NSCLC, Stage I
- Trial name
- NCT06404164
- Testing
- Wedge resection under watershed analysis method
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Guangdong Provincial People's Hospital
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- NCT03829332
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 162 sites in United States, Australia and 17 more
- Volunteers
- 623 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Plasma-Adapted First-Line Pembro In NSCLC
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and…
- Trial name
- NCT04166487
- Testing
- Pembrolizumab, PEMETREXED, CARBOPLATIN
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Julia K. Rotow, MD
Non-small Cell Lung Cancer, Carcinoma
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
This was a Phase 1/2, open-label, multicenter, single-arm study of combination therapy with ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, and durvalumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, in…
- Conditions
- Non-small Cell Lung Cancer, Carcinoma, NSCLC
- Trial name
- NCT02898116
- Testing
- Ensartinib, Durvalumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ludwig Institute for Cancer Research
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals